A porcine brain-derived peptide mixture with neurotrophic and neuroprotective properties, used clinically in several countries for stroke and dementia.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Cerebrolysin is a standardized neuropeptide preparation derived from the enzymatic hydrolysis of purified porcine brain proteins. It is not a single synthetic compound but rather a complex, chemically defined mixture consisting of approximately 25% low-molecular-weight peptides and peptide fragments alongside 75% free amino acids. The peptide fraction — which contains the bioactive components most relevant to its neurotrophic and neuroprotective properties — includes fragments with molecular weights below 10,000 daltons that are small enough to cross the blood-brain barrier following intravenous or intramuscular administration. The product is standardized to ensure consistent biological activity across manufacturing batches, an important quality consideration given its biological origin and complex composition.
Cerebrolysin is manufactured by EVER Pharma (formerly Ebewe Pharma) in Austria and has been approved for clinical use in more than 40 countries across Europe, Asia, Latin America, and parts of the Middle East for indications including acute ischemic stroke, traumatic brain injury, and various forms of dementia including Alzheimer’s disease. It has not received FDA approval for any indication in the United States, where it remains outside the scope of approved therapeutics and is classified as an investigational agent when studied in US-based clinical trials.
The scientific rationale for cerebrolysin centers on its ability to mimic the neurotrophic activity of endogenous growth factors — particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — in a form that bypasses the blood-brain barrier permeability limitations that prevent exogenous large protein growth factors from being delivered systemically. Decades of research, concentrated heavily in Eastern European, Russian, and Asian academic centers, have generated a substantial literature on cerebrolysin across acute neurological injury, chronic neurodegeneration, and cognitive impairment. However, the quality of this evidence base is uneven, with methodological criticisms including small sample sizes, non-standardized endpoints, and publication bias concerns applying to a significant portion of the older literature. More recent randomized controlled trials — including the CASTA stroke trial — have attempted to address these limitations.
This resource is provided for educational and research purposes only. Cerebrolysin is a prescription-only product in the countries where it is approved and is not available as an over-the-counter supplement. For mechanism comparisons with other neuropeptides, visit the Peptide Database, or explore evidence summaries through the AI Coach.
The central mechanistic hypothesis for cerebrolysin’s neurotrophic effects is its ability to activate the tropomyosin receptor kinase (Trk) family of neurotrophin receptors, specifically TrkA (the high-affinity receptor for nerve growth factor, NGF) and TrkB (the primary receptor for brain-derived neurotrophic factor, BDNF). Endogenous neurotrophins are relatively large proteins that cannot effectively cross the blood-brain barrier when administered peripherally, limiting their therapeutic utility as exogenous agents. Cerebrolysin’s bioactive peptide fragments appear to engage these receptors or their downstream signaling intermediaries in a manner that recapitulates key aspects of neurotrophin-mediated signaling. TrkA activation drives downstream signaling through Ras/ERK and PI3K/Akt pathways, promoting neuronal differentiation, neurite outgrowth, and survival of peripheral and central cholinergic neurons — cell populations of particular relevance to the memory deficits in Alzheimer’s disease. TrkB engagement activates similar survival cascades and additionally supports synaptic plasticity through AMPA receptor trafficking and dendritic spine remodeling. Preclinical data show that cerebrolysin treatment elevates BDNF immunoreactivity in hippocampal neurons and upregulates TrkB receptor expression in brain regions relevant to learning and memory, providing molecular-level evidence consistent with the clinical cognitive improvements observed in trial data. While the precise peptide sequences within cerebrolysin responsible for Trk receptor engagement have not been fully mapped — a limitation of working with a biological mixture rather than a defined synthetic peptide — the functional neurotrophin mimicry is reproducible across multiple independent preclinical and clinical research programs.
Downstream of neurotrophin receptor activation, cerebrolysin’s neuroprotective effects are substantially mediated through the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) pathway — one of the most critical intracellular survival signals in the nervous system. Akt phosphorylation downstream of PI3K activation leads to inactivation of pro-apoptotic proteins including BAD and the FOXO family of transcription factors, reducing mitochondrial cytochrome c release and caspase-9/-3 cascade activation. In ischemic settings, where ATP depletion and reactive oxygen species accumulation drive rapid neuronal apoptosis, PI3K/Akt pathway activation represents a direct brake on cell death that can significantly extend the survival window of neurons in the ischemic penumbra — the region of potentially salvageable tissue surrounding the infarct core. Cerebrolysin has been shown in rodent stroke models to reduce infarct volume and improve behavioral outcomes when administered within the therapeutic window, with molecular evidence pointing to preserved Akt phosphorylation as a contributing mechanism. Separately, cerebrolysin promotes phosphorylation of CREB — the cAMP response element-binding protein — which acts as a master regulator of neuroplasticity-related gene transcription. CREB target genes include BDNF itself, creating a potential positive feedback loop; c-Fos and Arc, which are required for long-term potentiation; and anti-apoptotic factors such as Bcl-2. This CREB-mediated transcriptional program supports both the acute neuroprotective and longer-term cognitive enhancement effects attributed to cerebrolysin in research settings.
Excitotoxicity — the pathological overstimulation of glutamate receptors, particularly NMDA receptors, leading to toxic calcium influx and neuronal death — is a central mechanism in both acute neurological injury (stroke, TBI) and chronic neurodegeneration. NMDA receptor overactivation depletes neuronal energy reserves, activates destructive proteases and lipases, and generates excessive reactive oxygen species that overwhelm antioxidant defenses. Cerebrolysin has been shown in preclinical studies to modulate NMDA receptor activity and attenuate excitotoxic calcium accumulation through mechanisms that appear to involve both post-synaptic receptor regulation and upstream synaptic glutamate handling. One proposed mechanism involves cerebrolysin-mediated enhancement of astrocytic glutamate uptake transporters, reducing synaptic glutamate availability before it can overactivate NMDA receptors. Additionally, components of the cerebrolysin peptide mixture may directly interact with modulatory sites on the NMDA receptor complex — though the specific peptide sequences responsible and their precise binding interactions remain areas of ongoing investigation. The clinical relevance of this mechanism is supported by the observation that cerebrolysin’s beneficial effects in stroke trials appear largest when administration begins early after symptom onset, consistent with the acute time-dependent nature of excitotoxic injury. Combined with its neurotrophic and anti-apoptotic mechanisms, NMDA receptor modulation positions cerebrolysin as a multi-target neuroprotective agent addressing several of the parallel injury cascades that converge in acute brain injury.
The Chinese Cerebrolysin Acute Stroke Trial in Ischemia (CASTA) represents the largest randomized, double-blind, placebo-controlled trial evaluating cerebrolysin in acute ischemic stroke and is the most methodologically rigorous piece of evidence in the compound’s clinical development history. The trial enrolled 1,070 patients with acute ischemic stroke within 72 hours of symptom onset across multiple Chinese hospital centers and randomized them to cerebrolysin (30 mL intravenous daily for 10 days) or placebo. The primary endpoint — favorable functional outcome defined as modified Rankin Scale score of 0–1 at 90 days — was not significantly different between groups (31.5% cerebrolysin versus 28.5% placebo, p=0.25). This null result on the primary endpoint was a significant finding that tempered earlier enthusiasm from smaller, predominantly positive trials. However, the trial showed positive signals on several pre-specified secondary neurological assessments including the National Institutes of Health Stroke Scale (NIHSS), where cerebrolysin-treated patients showed greater early improvement. A pre-specified subgroup analysis suggested that patients with more severe stroke deficits at baseline may have derived greater benefit. The CASTA investigators and subsequent meta-analyses have interpreted these findings as evidence of modest neurological benefit with less certainty about functional independence outcomes — a distinction that shapes how cerebrolysin is positioned in stroke treatment guidelines in countries where it is approved.
The evidence base for cerebrolysin in Alzheimer’s disease is considerably larger in volume than for any other indication, though its overall quality has been a subject of systematic review scrutiny. Multiple randomized controlled trials — predominantly from European, Russian, and Asian centers — have evaluated cerebrolysin across doses ranging from 10 to 30 mL intravenously administered daily or in repeated treatment cycles. A 2020 Cochrane Review identified 15 randomized trials involving 1,436 patients with Alzheimer’s disease or vascular dementia and concluded that there was low-certainty evidence suggesting cerebrolysin may improve cognitive function at six months (as measured by ADAS-Cog, MMSE, and global clinical impression scales) and that the compound was generally well-tolerated. The review noted significant limitations: unclear or high risk of bias in many included trials, substantial heterogeneity in protocols, and limited long-term follow-up. Mechanistically, the cognitive benefit is theorized to reflect cerebrolysin’s BDNF-mimetic effects on cholinergic neuronal survival in the basal forebrain — the cell population most critically affected in early Alzheimer’s pathology — and its CREB-mediated enhancement of synaptic plasticity in hippocampal circuits involved in memory formation. Whether cerebrolysin modifies disease progression versus symptom management alone remains an open and important question that adequately powered, long-duration trials have not yet resolved.
Traumatic brain injury represents a neurological indication where cerebrolysin’s multi-mechanistic neuroprotection profile is theoretically well-aligned with the complex injury cascade. TBI involves primary mechanical injury followed by a secondary injury phase characterized by excitotoxicity, oxidative stress, neuroinflammation, and apoptosis — each of which cerebrolysin’s mechanisms address to varying degrees. Clinical studies in TBI patients, primarily from Asian and Eastern European research groups, have evaluated cerebrolysin administered in the acute to subacute period and measured outcomes including neurological severity scores, consciousness level recovery, cognitive function, and neuroimaging parameters. A systematic review by Xing and colleagues identified consistent trends toward improved neurological outcomes in cerebrolysin-treated TBI patients across multiple studies, though again methodological quality limitations constrain the strength of conclusions. Preclinical TBI data from well-controlled rodent studies have shown cerebrolysin reduces cortical lesion volume, improves spatial navigation in Morris water maze testing, and preserves hippocampal neuronal density — findings consistent with the compound’s BDNF-mimetic and anti-apoptotic mechanisms. The lack of large multicenter RCTs specifically designed to current neuroprotective trial methodology standards in TBI represents the primary evidentiary gap for this indication.
A distinctive aspect of cerebrolysin’s research profile is the body of evidence from pediatric populations with cognitive development delays, perinatal brain injury sequelae, and attention-deficit disorders. Studies conducted primarily in Russian and Eastern European medical centers have evaluated cerebrolysin in children as young as three years with conditions including delayed psychospeech development, sequelae of perinatal hypoxic-ischemic encephalopathy, and pediatric TBI. These studies generally report improvements in neuropsychological assessment scores, language development metrics, and behavioral parameters. The neurotrophic rationale for pediatric application is compelling: the developing nervous system has high endogenous neurotrophin dependence, and early life neurological insults often result in persistent deficits in neurotrophin signaling and synaptic circuit formation. Cerebrolysin’s neurotrophin-mimetic activity could theoretically support neurodevelopmental recovery or compensation. However, the pediatric evidence base shares the methodological limitations of the broader cerebrolysin literature — small samples, non-standardized outcome measures, and geographic concentration in research traditions that may apply different methodological standards than those required for Western regulatory approval. No FDA or EMA-approved indication in pediatric patients exists, and any pediatric use of cerebrolysin must be considered investigational.
A clinically important dimension of cerebrolysin’s research profile is evidence suggesting synergistic benefit when the agent is combined with physical or cognitive rehabilitation protocols. The hypothesis is that cerebrolysin’s enhancement of neuroplasticity — through BDNF-mimetic TrkB activation, CREB phosphorylation, and synaptic remodeling — creates a neurobiological environment in which rehabilitation-driven activity-dependent plasticity is more effective. Studies examining cerebrolysin combined with physical therapy in stroke rehabilitation have reported greater functional improvement than rehabilitation alone. This concept of “pharmacological priming” for rehabilitation is mechanistically grounded in animal models showing that BDNF signaling is required for long-term potentiation and motor learning. The combination with cognitive training in dementia patients has similarly shown promising signals in small studies. These synergistic effects, if confirmed in rigorous trials, would have significant implications for how cerebrolysin is used clinically — not as a monotherapy but as an adjunct to standard rehabilitation programs in neurological care pathways.
In countries where cerebrolysin is approved, administration is exclusively parenteral — either intravenous or intramuscular — reflecting the peptide mixture’s requirement for direct systemic delivery to achieve meaningful CNS penetration. For acute ischemic stroke, the CASTA trial used 30 mL of cerebrolysin diluted in 100 mL of normal saline administered as a slow intravenous infusion once daily for 10 days, beginning within 72 hours of stroke onset. This 30 mL/day acute stroke dose represents the high end of the clinical dosing range. For Alzheimer’s disease and dementia, approved protocols in various countries typically involve 10–30 mL administered intravenously daily for 20–30 day treatment cycles, often repeated multiple times per year. Intramuscular administration at doses of 1–5 mL daily is an approved route for outpatient settings where intravenous access is impractical, though pharmacokinetic considerations suggest slower absorption and potentially lower peak CNS exposure compared to intravenous delivery. For dosing reference frameworks in neurological research contexts, explore our peptide calculators — noting that cerebrolysin dosing guidelines are based on approved labeling and clinical trial protocols rather than individualized calculation tools.
Cerebrolysin is commercially available as a clear, amber-colored solution in multiple concentration formats: 1 mL, 2 mL, 5 mL, 10 mL, and 30 mL ampoules at a standard concentration of 215.2 mg/mL total protein hydrolysate. The solution should be clear and free of visible particulate matter before use; any turbid or discolored solution should be discarded. For intravenous infusion, the ampoule contents are diluted into physiologically compatible solutions — normal saline or Ringer’s lactate — immediately before administration. Cerebrolysin is physically and chemically incompatible with several other injectable medications, and mixing in the same infusion bag should be avoided unless compatibility has been specifically verified. The product is stored at room temperature (15–25°C) and should not be frozen. Once diluted for infusion, the preparation should be used promptly and not stored.
In research settings outside of approved clinical indications, cerebrolysin has been studied at doses broadly consistent with the approved clinical range — most commonly 5–30 mL per day delivered intravenously for defined treatment courses. The lack of FDA approval means that any US-based research must proceed through IND (Investigational New Drug) application pathways with appropriate IRB oversight. Researchers in countries where cerebrolysin is approved have greater flexibility in protocol design within the bounds of their national regulatory frameworks. The compound’s biological origin and complex composition mean that lot-to-lot consistency, while controlled through manufacturing standards, is a consideration for preclinical and clinical researchers concerned about reproducibility. Any research use should consult the AI Coach and review primary literature for the most current protocol standards in each indication area.
Cerebrolysin is contraindicated in patients with known hypersensitivity to any component of the preparation, patients with epilepsy (due to theoretical risk of lowering seizure threshold at high doses), and patients with severe renal impairment (due to altered clearance of amino acid load). It should not be administered to patients with status epilepticus or in acute agitation states. Drug interactions have been identified with antidepressants — particularly monoamine oxidase inhibitors (MAOIs) — where additive CNS effects may occur; concurrent use should be approached with caution. The compound should not be combined in the same infusion with balanced amino acid solutions, lipid emulsions, or solutions with altered ionic balance. Pregnancy and lactation use is generally avoided given the absence of adequate safety data in these populations, and pediatric dosing in young children requires weight-adjusted protocols and specialized clinical oversight.
Cerebrolysin’s safety profile in clinical trials is generally characterized as favorable, with most adverse events being mild to moderate and transient. The most frequently reported adverse events during and after intravenous infusion include dizziness, headache, agitation, and mild gastrointestinal complaints including nausea. Infusion site reactions — mild redness, warmth, or discomfort at the intravenous access site — are occasionally reported. A small proportion of patients experience a sensation of warmth, tingling, or mild anxiety during rapid infusion, which is typically resolved by reducing the infusion rate. These hemodynamic-type reactions to intravenous administration are managed through slow infusion over 30–60 minutes and are less common with intramuscular delivery. Fatigue and sleep disturbances have been reported in a subset of patients, particularly during high-dose intravenous treatment courses. Overall, the adverse event profile documented in the CASTA trial and in Cochrane-reviewed Alzheimer’s disease trials supports a safety profile that does not raise major tolerability concerns at approved doses in appropriately selected patients.
As a biological preparation derived from porcine brain tissue, cerebrolysin carries a theoretical risk of hypersensitivity reactions that is distinct from the risk profile of synthetic peptides. Allergic reactions ranging from mild skin reactions to anaphylaxis have been reported in post-marketing experience, though the incidence appears to be low. Patients with known hypersensitivity to porcine proteins or prior reactions to biological preparations should not receive cerebrolysin. The complex mixture composition means that identifying the specific allergenic component in cases of hypersensitivity is generally not feasible, and re-challenge after a hypersensitivity reaction is not recommended. Prion disease transmission — a theoretical concern with any product derived from mammalian neural tissue — has been addressed through rigorous manufacturing standards and source material controls in EVER Pharma’s production process; no case of prion transmission attributable to cerebrolysin has been documented in the extensive clinical use history across more than five decades of use in approved markets. However, this theoretical concern is part of the regulatory context that influences the approach to approval in countries like the United States, where prion safety standards for biologicals are particularly stringent.
The theoretical risk of seizure precipitation with cerebrolysin in epilepsy patients is reflected in its contraindication in this population, though the mechanistic basis is not fully elucidated. The compound’s ability to modulate excitatory neurotransmission — including its effects on NMDA receptor activity — could theoretically lower seizure threshold in susceptible individuals. Clinically, cerebrolysin is used in post-stroke patients who have an inherently elevated seizure risk due to cortical injury, and the CASTA trial did not show excess seizure rates in treated patients, suggesting the theoretical risk is not prominently manifest in this population. The compound’s psychiatric effects in rare cases — including reports of agitation, confusion, and behavioral changes, particularly in older patients with cognitive impairment — warrant monitoring during treatment. These neurological adverse events are typically reversible upon dose reduction or treatment discontinuation. Long-term safety data beyond 12 months of repeated treatment courses is limited, representing a gap in the safety evidence base that prospective registries and long-term extension studies are beginning to address. For up-to-date safety information, the Peptide Database maintains summary data on reported adverse events across the neuropeptide class.
The FDA has not approved cerebrolysin for any indication in the US for several overlapping reasons. The regulatory standard for drug approval in the US requires demonstration of safety and efficacy in well-controlled pivotal trials conducted under FDA oversight — a bar that the predominantly European and Asian cerebrolysin clinical literature has not been designed or powered to meet. Concerns about the biological mixture’s compositional complexity, manufacturing consistency across batches, and the prion safety standards required for products of central nervous system animal origin have also contributed to the regulatory pathway challenges. Additionally, Novo Nordisk never pursued US approval, and current manufacturer EVER Pharma has not submitted an NDA. Conducting FDA-compliant Phase 3 trials for US approval would require substantial investment that the pharmaceutical economics of an older, generically-priced biological product may not support.
In the 40+ countries where cerebrolysin has regulatory approval, approved indications typically include acute ischemic stroke (acute treatment and rehabilitation), traumatic brain injury, and dementia syndromes including Alzheimer’s disease and vascular dementia. Some national approvals extend to ischemic stroke prevention, post-stroke rehabilitation, and pediatric neurological development disorders. The specific approved indications, doses, and treatment protocols vary by country, reflecting the different regulatory review processes and evidence standards applied in each jurisdiction. Prescribing should follow the locally approved labeling.
No. Cerebrolysin must be administered parenterally — intravenously or intramuscularly. The bioactive peptide components are degraded by gastrointestinal proteases upon oral ingestion and do not reach systemic circulation in intact, pharmacologically active form. Products marketed as “oral cerebrolysin” or supplements claiming to replicate its effects via oral route do not contain the same pharmacologically characterized peptide mixture and lack the clinical evidence base associated with the injected preparation. Any injectable cerebrolysin that is not sourced from the approved pharmaceutical manufacturer (EVER Pharma) and administered under medical supervision carries serious safety risks including contamination, dosing errors, and unknown compositional characteristics.
Exogenous BDNF and NGF are large proteins (approximately 13–27 kDa) that cannot effectively cross the blood-brain barrier when administered peripherally, limiting their therapeutic utility to direct intracerebral injection — a highly invasive approach. Cerebrolysin achieves neurotrophin-like biological activity with low-molecular-weight peptide fragments that can cross the BBB after systemic administration, making it a clinically practical alternative to direct neurotrophin delivery. It does not contain intact BDNF or NGF molecules; rather, specific peptide sequences within the mixture appear to activate TrkA and TrkB receptor signaling in a functionally analogous manner. This mechanistic positioning is why cerebrolysin is sometimes described as a “neurotrophin mimetic” rather than a simple neurotrophic factor preparation.
CASTA (Chinese Cerebrolysin Acute Stroke Trial in Ischemia) was a 1,070-patient multicenter randomized placebo-controlled trial evaluating cerebrolysin in acute ischemic stroke. The primary endpoint — favorable functional outcome (modified Rankin Scale 0-1) at 90 days — was not significantly different between cerebrolysin and placebo groups. However, secondary neurological outcome measures favored cerebrolysin, particularly in patients with more severe deficits at baseline. The trial is important as the largest methodologically rigorous cerebrolysin stroke study and is frequently cited as the definitive evidence on both sides of the debate about cerebrolysin’s stroke indication.
Clinical trials and a Cochrane systematic review suggest cerebrolysin may improve cognitive assessments in Alzheimer’s disease patients relative to placebo, with low-to-moderate certainty evidence of modest effect sizes on standardized cognitive scales. The evidence does not firmly establish whether this represents disease modification or symptomatic improvement. Cerebrolysin is used for Alzheimer’s disease in several approved markets and is considered an adjunctive treatment option in those regions. It is not an approved treatment in the US or EU and is not recommended as a substitute for standard-of-care Alzheimer’s therapies like cholinesterase inhibitors or anti-amyloid biologics.
Cerebrolysin is derived from porcine (pig) brain tissue that undergoes standardized enzymatic hydrolysis under controlled manufacturing conditions. The theoretical concern about prion disease transmission from neural tissue-derived products has been addressed through: sourcing from closed, health-monitored pig herds in prion-free regions; implementation of manufacturing steps validated to reduce prion infectivity; and decades of clinical use without documented prion transmission. While the theoretical risk cannot be mathematically reduced to zero, the absence of prion disease cases attributable to cerebrolysin across more than 50 years of use in millions of patients in approved markets is a meaningful real-world safety data point.
Treatment course duration varies by indication. For acute stroke, the most studied protocol is 10 days of daily intravenous infusion beginning within 72 hours of onset. For chronic conditions like Alzheimer’s disease, treatment is typically delivered in cycles: 20–30 days of daily infusion, followed by a treatment-free interval, then repeated. The number of cycles per year and the total duration of treatment varies by clinical protocol and national prescribing guidelines. Long-term maintenance protocols involving seasonal treatment cycles (2–4 times per year) are used in some approved markets for dementia management. The rationale for cyclical rather than continuous administration relates to the biological nature of the product and historical clinical experience suggesting that periodic re-exposure with intervals maintains benefit while minimizing tolerance development.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.